The altered expression of HANR affects the sensitivity of HCC to doxorubicin by suppressing glycogen synthase kinase-3 beta (GSK3β) phosphorylation and upregulating GSK3β total protein expression. Here, RPL13AP20 is linked to hepatocellular carcinoma.